Challenges in Conducting Clinical Trials for Preeclampsia.
Curr Hypertens Rep
; 26(2): 59-68, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-37971596
ABSTRACT
PURPOSE OF REVIEW To review recent data describing the challenges and innovations in therapeutic research focused on the prevention and treatment of preeclampsia. RECENT FINDINGS:
Pregnant individuals have traditionally been excluded from therapeutic research, resulting in a paucity of innovation in therapeutics for pregnancy-specific medical conditions, especially preeclampsia. With the increased awareness of maternal morbidity and mortality, there is significant interest among researchers to expand therapeutic research in pregnancy. Several medications, including aspirin, pravastatin, metformin, and esomeprazole, which are commonly used in non-pregnant populations, are now being investigated for preeclampsia prevention. However, given the historic precedent of exclusion, along with the regulatory, ethical, and feasibility concerns that accompany this population, the study of these and novel medications has been complicated by numerous challenges. While complex, and laden with challenges, there is great ongoing need for therapeutic research to address preeclampsia. Aspirin, pravastatin, metformin, and esomeprazole have all shown promise as potential therapeutic agents; however, their use remains to be optimized, and innovative therapeutics need to be developed.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Preeclampsia
/
Complicaciones del Embarazo
/
Hipertensión
/
Metformina
Límite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Curr Hypertens Rep
Asunto de la revista:
ANGIOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos